CD4 and neoplasm: Increasing evidence suggests that tumor-infiltrating immune cells determine the clinical outcome of immunotherapy in different sarcoma subtypes.10, 11, 12, 13 Immunosurveillance is mediated in part by two major groups of T cells (CD4+, CD8+), which play a pivotal role in tumor formation, tumor progression, and therapy.14